BioInvent International (BINV) Corporate presentation summary

Strategic focus and pipeline overview

• Developing first-in-class immune-modulating antibodies for cancer, with four ongoing clinical programs and operations funded through Q1 2027.

• Proprietary F.I.R.S.T™ platform enables discovery of novel oncology targets and high-quality antibodies, fueling pipeline expansion.

• Listed on NASDAQ OMX Stockholm MidCap, with a strong international investor base.

BI-1808 (anti-TNFR2) clinical progress

• Demonstrates single-agent and combination efficacy in ovarian cancer, CTCL, and other solid tumors, with observed complete and partial responses.

• In ovarian cancer, 24% ORR and 57% DCR in Phase 2a with pembrolizumab; strong activity in both high-grade serous and clear cell subtypes.

• Mechanism involves Treg depletion and myeloid cell reprogramming, converting "cold" tumors to "hot" and synergizing with PD-1 blockade.

• Triplet regimen with pembrolizumab and paclitaxel aims to surpass current standard of care, with pivotal data expected H2 2026.

• Promising efficacy and safety in CTCL and PTCL, with 40% ORR as monotherapy and 50% ORR in combination with pembrolizumab.

BI-1206 (anti-FcyRIIB) clinical progress

• Overcomes rituximab resistance in NHL, showing 59% ORR and 41% CRR in FL as doublet, and 80% ORR in triplet with rituximab and acalabrutinib.

• Well-tolerated with no severe toxicities, offering a convenient alternative to bispecifics and CAR-T in community settings.

• In solid tumors, combination with pembrolizumab shows durable responses in anti-PD-1 refractory melanoma and uveal melanoma.

• Phase 2a studies ongoing in 1st-line NSCLC and uveal melanoma, with first data readouts expected H2 2026.